Jecko Thachil: Interrupting Antiplatelet Therapy for Urgent and Planned Surgery
Jecko Thachil, MAHSC Professor, at the University of Manchester, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Cardiovascular and cerebrovascular diseases are major causes of morbidity and morality in the world. Antiplatetelet therapies play a major role in the management of these conditions.
But when a patient receiving antiplatelet medications requires urgent or planned surgery, how do we deal with interrupting these treatments? Discussed in the following review.”
Title: How to undertake procedures while on antiplatelet agents: a hematologist’s view
Authors: Dawn Swan, Robert Turner, James Douketis, Jecko Thachil
Read the Full Article on RPTH.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 4, 2026, 16:17Nada Fahd: Immune Thrombocytopenia (ITP) – Outpatient vs Inpatient Management
-
Jun 4, 2026, 16:16Saoud Hassan: Hemostasis and Blood Coagulation Pathway – Simplified
-
Jun 4, 2026, 16:15Farooq Khan: Vacuuming Blood Clots in Seconds
-
Jun 4, 2026, 16:14Kayla Garrett: Confirming Or Excluding APS Relies On Accurate Lupus Anticoagulant Testing
-
Jun 4, 2026, 16:14Scott Colton: Exploring the Key Differences Between Anticoagulant and Antiplatelet Medications
-
Jun 4, 2026, 16:13Wolfgang Miesbach: Is Bone Health a Silent Comorbidity In Haemophilia and VWD?
-
Jun 4, 2026, 15:35Carolina La Mura: Insights from the LATAM Hemophilia Forum 2026
-
Jun 4, 2026, 15:25Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia